Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Mupirocin

FDA-approved product (ointment, topical), marketed as Bactroban, Centany, Mupirocin.

Registered studies
50+
Lab records
16
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Mupirocin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Impetigo
  • Infection
  • Nasal congestion

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antibiotics for topical use; Other nasal preparations
FDA pharmacologic class
RNA Synthetase Inhibitor Antibacterial FDA label ↗
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC D06AX09; FDA class RNA Synthetase Inhibitor Antibacterial

Repurposing investigation

Mupirocin is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA75.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli82.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae71.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis42.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • MRSA: measured active in 6 of 10 lab records
  • E. coli: measured active in 1 of 2 lab records
  • K. pneumoniae: measured active in 2 of 4 lab records
Open Mupirocin in ChEMBL Registered studies below
Show the 16 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Mupirocin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Chlorhexidine Gluconate Versus Mupirocin Ointment in the Prevention of Peritoneal Dialysis-Related Infection

    NCT02547103 · start 2016-06-01

    Registered record
    Registry ID
    NCT02547103
    Conditions
    End Stage Renal Disease; Peritoneal Dialysis
    Interventions
    Chlorhexidine gluconate-soaked cloths; Normal saline; mupirocin ointment
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2016-06-01
    Completion
    2021-08
    Enrolment
    354

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEnd Stage Renal Disease; Peritoneal Dialysis
    InterventionChlorhexidine gluconate-soaked cloths; Normal saline; mupirocin ointment
    PhasePhase 4
    Registry statusUnknown

  • Preoperative Decolonization and Surgical Site Infections - a Prospective Randomized Trial

    NCT02560155 · start 2015-11

    Registered record
    Registry ID
    NCT02560155
    Conditions
    Orthopedic Disorders; Surgical Site Infection
    Interventions
    Mupirocin 2% nasal ointement; Chlorhexidine sol 4%
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2015-11
    Completion
    2018-02
    Enrolment
    1,300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOrthopedic Disorders; Surgical Site Infection
    InterventionMupirocin 2% nasal ointement; Chlorhexidine sol 4%
    PhaseNot applicable
    Registry statusCompleted

  • Effect of Mupirocin Dressings Versus Island Dressings on Surgical Site Infections in Elective Colorectal Surgery

    NCT02619773 · start 2015-11

    Registered record
    Registry ID
    NCT02619773
    Conditions
    Surgical Site Infections
    Interventions
    mupirocin ointment
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2015-11
    Completion
    2018-12
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSurgical Site Infections
    Interventionmupirocin ointment
    PhaseNot applicable
    Registry statusCompleted

  • Treating Parents to Reduce NICU Transmission of Staphylococcus Aureus Trial

    NCT02223520 · start 2014-11

    Registered record
    Registry ID
    NCT02223520
    Conditions
    Staph Aureus Colonization; Staph Aureus Infection
    Interventions
    Mupirocin and Chlorhexidine; Placebo ointment and placebo cloths
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2014-11
    Completion
    2019-10-31
    Enrolment
    307

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStaph Aureus Colonization; Staph Aureus Infection
    InterventionMupirocin and Chlorhexidine; Placebo ointment and placebo cloths
    PhaseNot applicable
    Registry statusCompleted

  • Human Microbiome and Healthcare Associated Infections - Nursing Home Dwelling Older Veterans

    NCT04218799 · start 2014-08-12

    Registered record
    Registry ID
    NCT04218799
    Conditions
    Human Microbiome
    Interventions
    Intranasal Mupirocin and Topical Chlorhexidine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2014-08-12
    Completion
    2015-09-22
    Enrolment
    19

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHuman Microbiome
    InterventionIntranasal Mupirocin and Topical Chlorhexidine
    PhasePhase 4
    Registry statusCompleted

  • S. Aureus Screening and Decolonization

    NCT02182115 · start 2014-07

    Registered record
    Registry ID
    NCT02182115
    Conditions
    Wound Infection Due to Staphylococcus Aureus; MRSA Infection of Postoperative Wound
    Interventions
    antiseptic bundle; standard of care
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2014-07
    Completion
    2016-08
    Enrolment
    110

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionWound Infection Due to Staphylococcus Aureus; MRSA Infection of Postoperative Wound
    Interventionantiseptic bundle; standard of care
    PhasePhase 4
    Registry statusCompleted

  • Safety and Efficacy of Mupirocin in Eradicating Colonization With S. Aureus in Critically Ill Infants

    NCT01827358 · start 2014-04-30

    Registered record
    Registry ID
    NCT01827358
    Conditions
    Staphylococcal Infection
    Interventions
    Mupirocin calcium; Mupirocin calcium
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2014-04-30
    Completion
    2016-06-21
    Enrolment
    155

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStaphylococcal Infection
    InterventionMupirocin calcium; Mupirocin calcium
    PhasePhase 2
    Registry statusCompleted

  • Impact of Mupirocin Decolonization on the Nasal Microbiome

    NCT02045329 · start 2013-10

    Registered record
    Registry ID
    NCT02045329
    Conditions
    Nasal Colonization With Staph Aureus
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Terminated
    Start
    2013-10
    Completion
    2015-06-05
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNasal Colonization With Staph Aureus
    InterventionNot recorded
    PhaseNot recorded
    Registry statusTerminated

  • Persistent Methicillin Resistant Staphylococcus Aureus Eradication Protocol (PMEP)

    NCT01594827 · start 2012-10

    Registered record
    Registry ID
    NCT01594827
    Conditions
    Cystic Fibrosis
    Interventions
    Inhaled Vancomycin; Placebo (Sterile Water); Rifampin; Trimethoprim/Sulfamethoxazole (TMP/SMX); Doxycycline; Mupirocin Intranasal Creme; 4% chlorhexidine gluconate liquid skin cleanser
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2012-10
    Completion
    2017-12-30
    Enrolment
    29

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCystic Fibrosis
    InterventionInhaled Vancomycin; Placebo (Sterile Water); Rifampin; Trimethoprim/Sulfamethoxazole (TMP/SMX) +3 more
    PhasePhase 2
    Registry statusCompleted

  • Retapamulin for Reducing MRSA Nasal Carriage

    NCT01461668 · start 2012-07

    Registered record
    Registry ID
    NCT01461668
    Conditions
    Methicillin-Resistant Staphylococcus Aureus
    Interventions
    Retapamulin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2012-07
    Completion
    2017-12
    Enrolment
    53

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMethicillin-Resistant Staphylococcus Aureus
    InterventionRetapamulin; Placebo
    PhasePhase 4
    Registry statusCompleted

  • Total Occlusive Ionic Silver-containing Dressing vs Mupirocin Ointment Application vs Conventional Dressing in Elective Colorectal Surgery: Effect on Incisional Surgical Site Infection

    NCT02267122 · start 2012-01

    Registered record
    Registry ID
    NCT02267122
    Conditions
    Incisional Surgical Site Infections
    Interventions
    ionic silver-containing dressing; Mupirocin ointment application
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-01
    Completion
    2014-01
    Enrolment
    147

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIncisional Surgical Site Infections
    Interventionionic silver-containing dressing; Mupirocin ointment application
    PhasePhase 3
    Registry statusCompleted

  • The Use of Antibiotic Sinonasal Rinse After Sinus Surgery

    NCT02218307 · start 2011-11

    Registered record
    Registry ID
    NCT02218307
    Conditions
    Chronic Rhinosinusitis
    Interventions
    Mupirocin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2011-11
    Completion
    2015-06
    Enrolment
    68

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Rhinosinusitis
    InterventionMupirocin; Placebo
    PhasePhase 4
    Registry statusCompleted

  • Early Methicillin-resistant Staphylococcus Aureus (MRSA) Therapy in Cystic Fibrosis (CF)

    NCT01349192 · start 2011-04

    Registered record
    Registry ID
    NCT01349192
    Conditions
    Cystic Fibrosis; Methicillin-resistant Staphylococcus Aureus
    Interventions
    Rifampin; Trimethoprim/Sulfamethoxazole; Minocycline; Mupirocin; chlorhexidine gluconate oral rinse; 2% Chlorhexidine solution wipes; Environmental Decontamination
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2011-04
    Completion
    2015-05
    Enrolment
    47

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCystic Fibrosis; Methicillin-resistant Staphylococcus Aureus
    InterventionRifampin; Trimethoprim/Sulfamethoxazole; Minocycline; Mupirocin +3 more
    PhasePhase 2
    Registry statusTerminated

  • Prevention of Surgical Site Infections: Effectiveness of Nasal Povidone-Iodine and Nasal Mupirocin

    NCT01313182 · start 2011-03

    Registered record
    Registry ID
    NCT01313182
    Conditions
    Surgical Site Infection
    Interventions
    mupirocin calcium ointment, 2%; 3M Skin and Nasal Antiseptic
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2011-03
    Completion
    2012-09
    Enrolment
    1,874

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSurgical Site Infection
    Interventionmupirocin calcium ointment, 2%; 3M Skin and Nasal Antiseptic
    PhasePhase 4
    Registry statusCompleted

  • Timolol Option for Ulcerated Hemangiomas (TOUCH Trial)

    NCT01408056 · start 2011-02

    Registered record
    Registry ID
    NCT01408056
    Conditions
    Infantile Hemangiomas
    Interventions
    Timolol 0.5% Gel Forming Solution (GFS); Mupirocin 2% Ointment
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2011-02
    Completion
    2014-01
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfantile Hemangiomas
    InterventionTimolol 0.5% Gel Forming Solution (GFS); Mupirocin 2% Ointment
    PhasePhase 2
    Registry statusWithdrawn